Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 8;14(22):5480.
doi: 10.3390/cancers14225480.

A GNAS Gene Mutation's Independent Expression in the Growth of Colorectal Cancer: A Systematic Review and Meta-Analysis

Hafeez Abiola Afolabi  1 , Salzihan Md Salleh  2   3 , Zaidi Zakaria  1 , Ewe Seng Ch'ng  4 , Siti Norasikin Mohd Nafi  3 , Ahmad Aizat Bin Abdul Aziz  5 , Ahmad Adebayo Irekeola  6 , Yusuf Wada  6 , Sameer Badri Al-Mhanna  7
Affiliations
Review

A GNAS Gene Mutation's Independent Expression in the Growth of Colorectal Cancer: A Systematic Review and Meta-Analysis

Hafeez Abiola Afolabi et al. Cancers (Basel). .

Abstract

Globally, colorectal carcinoma CRC is the third most common cancer and the third most common reason for cancer-associated mortality in both genders. The GNAS mutations are significantly linked with poor prognosis and failed treatment outcomes in CRC. A systematic review and meta-analysis of multiple studies executed following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) criteria and registered with PROSPERO (registration number: CRD42021256452). The initial search includes a total of 271 publications; however, only 30 studies that merit the eligibility criteria were eventually chosen. Data analysis via OpenMeta Analyst and comprehensive meta-analysis 3.0 (CMA 3.0) software were used to investigate the prevalence of GNAS gene mutation among CRC patients. The meta-analysis consisted of 10,689 participants with most being males 6068/10,689 (56.8%). Overall, prevalence of GNAS mutations was 4.8% (95% CI: 3.1−7.3) with I2 = 94.39% and (p < 0.001). In 11/30 studies, the frequency of GNAS gene mutations was majorly in codons R201C [40.7% (95% CI: 29.2−53.2%)] and in codon R201H [39.7% (95% CI = 27.1−53.8)]. Overall prevalence of GNAS mutations was highest among the male gender: 53.9% (95% CI: 48.2−59.5%: I2 = 94.00%, (p < 0.001), tumour location (colon): 50.5% (95% CI: 33.2−67.6%: I2 = 97.93%, (p < 0.001), tumour grade (Well): 57.5% (95% CI: 32.4−79.2%: I2 = 98.10%, (p < 0.001) and tumour late stage: 67.9% (95% CI: 49.7−84.3%: I2 = 98.%, (p < 0.001). When stratified according to study location, a higher prevalence was observed in Japan (26.8%) while Italy has the lowest (0.4%). Overall prevalence of GNAS gene mutations was 4.8% with codons R201C and R201H being the most mutated, and the results conformed with numerous published studies on GNAS mutation.

Keywords: CRC; GNAS gene mutations; colon cancer; colorectal cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Summary of article identification and selection process.
Figure 2
Figure 2
Forest plot for the prevalence of GNAS mutation in CRC patients [1,6,12,14,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45].
Figure 3
Figure 3
Forest plot for GNAS codon R201C in CRC patients [1,6,14,22,24,33,36,37,38,39,43].
Figure 4
Figure 4
Forest plot for GNAS codon R201H in CRC patients [1,6,14,22,24,33,36,37,38,39,42].
Figure 5
Figure 5
GNAS Funnel Plot Funnel plot showing no significant publication bias (Egger’s p = 0.12281).
See this image and copyright information in PMC

References

    1. Zauber P., Marotta S.P., Sabbath-Solitare M. GNAS Gene Mutation May Be Present Only Transiently during Colorectal Tumorigenesis. Int. J. Mol. Epidemiol. Genet. 2016;7:24–31. - PMC - PubMed
    1. Fadaka A.O., Bakare O.O., Pretorius A., Klein A. Genomic Profiling of MicroRNA Target Genes in Colorectal Cancer. Tumor Biol. 2020;42 doi: 10.1177/1010428320933512. - DOI - PubMed
    1. Zhang Z., Tan X., Luo J., Cui B., Lei S., Si Z., Shen L., Yao H. GNA 13 Promotes Tumor Growth and Angiogenesis by Upregulating CXC Chemokines via the NF-κB Signaling Pathway in Colorectal Cancer Cells. Cancer Med. 2018;7:5611–5620. doi: 10.1002/cam4.1783. - DOI - PMC - PubMed
    1. Steffen D.J., Amornphimoltham P., Valera J.L.C., Taylor S., Hunter T., Tamayo P., Gutkind J.S. GNAS-PKA Oncosignaling Network in Colorectal Cancer. FASEB J. 2018;32:695–699. doi: 10.1096/fasebj.2018.32.1_supplement.695.9. - DOI
    1. Ohtsuka T., Tomosugi T., Kimura R., Nakamura S., Miyasaka Y., Nakata K., Mori Y., Morita M., Torata N., Shindo K. Clinical Assessment of the GNAS Mutation Status in Patients with Intraductal Papillary Mucinous Neoplasm of the Pancreas. Surg. Today. 2019;49:887–893. doi: 10.1007/s00595-019-01797-7. - DOI - PubMed

LinkOut - more resources